摘要
目的观察和比较重组人血管内皮抑素(恩度)联合培美曲塞与单药培美曲塞治疗方案在70岁以上的老年进展期肺腺癌中的疗效和安全性。方法选择50例进展期肺腺癌的老年患者,其中恩度联合培美曲塞组26例,培美曲塞单药组24例,观察比较两组有效率、疾病控制率及不良反应。结果恩度联合培美曲塞组完全缓解(CR)0例,部分缓解(PR)6例,稳定(SD)15例,有效率(CR+PR)为23.1%,疾病控制率(CR+PR+SD)为80.8%。培美曲塞单药组CR 0例,PR 4例,SD9例,有效率为16.7%,疾病控制率为54.2%。两组比较,有效率差异无统计学意义(P>0.05),但疾病控制率的差异具有统计学意义(P<0.05)。两组患者不良反应主要为骨髓抑制及胃肠道反应,均可耐受。结论在70岁以上老年进展期肺腺癌的治疗中,恩度与培美曲塞联合应用可提高临床疗效,并且耐受性良好。
[ Objective ] To observe the efficacy and safety of rh-endostatin combined with pemetrexed in the treatment of elder advanced lung adenocarcinoma. [ Methods ] 50 patients above 70 years old with advanced lung adenocarcinoma were devided into pemetrexed group（24 cases） and rh-endostatin combined with pemetrexed group（26 cases）. Observe and compare the response rate（RR） ,disease control rate（DCR）and adverse events（AEs） of the two groups. [ Resluts ] There were 0 case CR,6 cases PR,15 cases SD in the group of rh-endostatin combined with pemetrexed,and the response rate was 23.1%,disease control rate was 80.8%.In the pemetrexed group,there were 0 case CR,4 cases PR,9 cases SD, and the response rate was 16.7%,disease control rate was 54.2%.The response rate of the two groups had no significant difference（P〉0.05）. But there was a significant difference in the disease control rate between the two groups. The main adverse events of the two groups were myelosuppression and gastrointestinal reactions which were tolerant. [ Conclusion ] Rh-endostatin combined with pemetrexed in the lung adenocarcinoma is safe and effective.
出处
《中国医学工程》
2013年第11期15-16,18,共3页
China Medical Engineering
关键词
重组人血管内皮抑素
培美曲塞
肺肿瘤
rh-endostatin
Pemetrexed
lung neoolasms treatment of patients above 70 years old with advanced
